Hierarchy, tolerance, and dominance in the antitumor T-cell response

Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.

Gene therapy·2015

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.

Gene therapy·2012

Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.

Gene therapy·2008

B16 as a mouse model for human melanoma.

Current protocols in immunology·2008

Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.

Cancer research·2001

Immunization against endogenous retroviral tumor-associated antigens.

Cancer research·2001

Armoring CAR-T Cells Against Exhaustion: Engineering Strategies for Glioblastoma.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026

Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcomes in Three Patients.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026

IGF2BP3-Mediated m6A Modification of OLR1 mRNA Promotes Immune Evasion in CRC via the PI3K/AKT/mTOR Pathway.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026

Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term Remission.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026

Identifying Patients at Risk for Immune Checkpoint Inhibitor-Induced Colitis: Evidence From a Real-World Oncology Cohort.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026

Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates.

Journal of immunotherapy (Hagerstown, Md. : 1997)·2026

Concurrent Kaposi Sarcoma and B-cell Lymphoma in an HIV-Negative Patient: A Case Report.

Cureus·2026

A Tumor-Microenvironment-Responsive Chemically Masked IL‑2 Prodrug Potentiates PD‑1 Checkpoint Blockade and Elicits Robust Antitumor Efficacy.

ACS central science·2026

Nanotechnology-enabled immunomodulation in esophageal cancer: targeting the tumor microenvironment to overcome therapeutic barriers.

Frontiers in immunology·2026

Interpretation of p53 immunohistochemical stain of TP53-mutated myeloid neoplasms.

Frontiers in oncology·2026

miR-155-5p drives coordinated tumor and macrophage reprogramming across multiple cancer entities.

BMC medicine·2026

Imaging features of soft tissue hibernoma: a review of 73 cases.

Skeletal radiology·2026

Related Experiment Videos

Hierarchy, tolerance, and dominance in the antitumor T-cell response

Related Concept Videos

Enhanced T-cell activation and differentiation in lymphocytes from transgenic mice expressing ubiquitination-resistant 2KR LAT molecules.

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.

Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.

B16 as a mouse model for human melanoma.

Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.

Immunization against endogenous retroviral tumor-associated antigens.

Armoring CAR-T Cells Against Exhaustion: Engineering Strategies for Glioblastoma.

Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: Clinical Presentation and Outcomes in Three Patients.

IGF2BP3-Mediated m6A Modification of OLR1 mRNA Promotes Immune Evasion in CRC via the PI3K/AKT/mTOR Pathway.

Local Therapy for Isolated Residual Metastatic Melanoma and Renal Cell Carcinoma Following Immune Checkpoint Inhibition Leading to Long-Term Remission.

Identifying Patients at Risk for Immune Checkpoint Inhibitor-Induced Colitis: Evidence From a Real-World Oncology Cohort.

Internalization-Dependent EGFR-Targeted Photoactivation by Cetuximab-I21 Conjugates.

Concurrent Kaposi Sarcoma and B-cell Lymphoma in an HIV-Negative Patient: A Case Report.

A Tumor-Microenvironment-Responsive Chemically Masked IL‑2 Prodrug Potentiates PD‑1 Checkpoint Blockade and Elicits Robust Antitumor Efficacy.

Nanotechnology-enabled immunomodulation in esophageal cancer: targeting the tumor microenvironment to overcome therapeutic barriers.

Interpretation of p53 immunohistochemical stain of TP53-mutated myeloid neoplasms.

miR-155-5p drives coordinated tumor and macrophage reprogramming across multiple cancer entities.

Imaging features of soft tissue hibernoma: a review of 73 cases.

Related Experiment Videos

Hierarchy, tolerance, and dominance in the antitumor T-cell response

Related Concept Videos

Related Articles